Why Model Medicines needs to ‘discover new colors’ in its AI drug discovery quest

When Daniel Haders, Ph.D., was working in venture capital, he was on the hunt for an AI-driven drug discovery company that truly deserved his investment. “Outliers are what you're going for,” Model Medicines CEO Daniel Haders, Ph.D., told Fierce to explain the company's AI-driven drug development strategy. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry…

Source: FierceBiotech